Suppr超能文献

FTY720(吉仑他滨)对鞘氨醇 1-磷酸受体亚型 1(S1P1)G 蛋白偶联受体的磷酸选择性需要细胞内环 1 和跨膜域 2 中的基序。

FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2.

机构信息

Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163.

Department of Chemistry, Computational Research on Materials Institute, University of Memphis, Memphis, Tennessee 38152.

出版信息

J Biol Chem. 2011 Sep 2;286(35):30513-30525. doi: 10.1074/jbc.M111.263442. Epub 2011 Jun 30.

Abstract

FTY720 phosphate (FTY720P) is a high potency agonist for all the endothelial differentiation gene family sphingosine 1-phosphate (S1P) receptors except S1P receptor subtype 2 (S1P(2)). To map the distinguishing features of S1P(2) ligand recognition, we applied a computational modeling-guided mutagenesis strategy that was based on the high degree of sequence homology between S1P(1) and S1P(2). S1P(2) point mutants of the ligand-binding pocket were characterized. The head group-interacting residues Arg3.28, Glu3.29, and Lys7.34 were essential for activation. Mutation of residues Ala3.32, Leu3.36, Val5.41, Phe6.44, Trp6.48, Ser7.42, and Ser7.46, predicted to interact with the S1P hydrophobic tail, impaired activation by S1P. Replacing individual or multiple residues in the ligand-binding pocket of S1P(2) with S1P(1) sequence did not impart activation by FTY720P. Chimeric S1P(1)/S1P(2) receptors were generated and characterized for activation by S1P or FTY720P. The S1P(2) chimera with S1P(1) sequence from the N terminus to transmembrane domain 2 (TM2) was activated by FTY720P, and the S1P(2)(IC1-TM2)(S1P1) domain insertion chimera showed S1P(1)-like activation. Twelve residues in this domain, distributed in four motifs a-d, differ between S1P(1) and S1P(2). Insertion of (78)RPMYY in motif b alone or simultaneous swapping of five other residues in motifs c and d from S1P(1) into S1P(2) introduced FTY720P responsiveness. Molecular dynamics calculations indicate that FTY720P binding selectivity is a function of the entropic contribution to the binding free energy rather than enthalpic contributions and that preferred agonists retain substantial flexibility when bound. After exposure to FTY720P, the S1P(2)(IC1-TM2)(S1P1) receptor recycled to the plasma membrane, indicating that additional structural elements are required for the selective degradative trafficking of S1P(1).

摘要

FTY720 磷酸盐(FTY720P)是所有内皮分化基因家族鞘氨醇 1-磷酸(S1P)受体的高活性激动剂,除了 S1P 受体亚型 2(S1P(2))。为了绘制 S1P(2)配体识别的区别特征,我们应用了一种基于 S1P(1)和 S1P(2)之间高度序列同源性的计算建模指导的诱变策略。对配体结合口袋的 S1P(2)点突变体进行了表征。头部相互作用残基 Arg3.28、Glu3.29 和 Lys7.34 对于激活是必需的。预测与 S1P 疏水性尾部相互作用的残基 Ala3.32、Leu3.36、Val5.41、Phe6.44、Trp6.48、Ser7.42 和 Ser7.46 的突变损害了 S1P 的激活。用 S1P(1)序列替换 S1P(2)配体结合口袋中的单个或多个残基,不会赋予 FTY720P 的激活。生成并表征了嵌合 S1P(1)/S1P(2)受体,以研究 S1P 或 FTY720P 的激活。从 N 末端到跨膜域 2(TM2)的 S1P(1)序列的 S1P(2)嵌合体被 FTY720P 激活,并且 S1P(2)(IC1-TM2)(S1P1)结构域插入嵌合体显示出 S1P(1)样激活。该结构域中的 12 个残基,分布在四个基序 a-d 中,在 S1P(1)和 S1P(2)之间存在差异。仅基序 b 中的(78)RPMYY 插入或同时从 S1P(1)交换基序 c 和 d 中的五个其他残基到 S1P(2)中,引入了 FTY720P 反应性。分子动力学计算表明,FTY720P 结合选择性是结合自由能的熵贡献的函数,而不是焓贡献,并且当结合时,优选的激动剂保持相当大的灵活性。暴露于 FTY720P 后,S1P(2)(IC1-TM2)(S1P1)受体再循环到质膜,表明选择性降解贩运 S1P(1)需要额外的结构元件。

相似文献

2
Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors.
J Neurochem. 2007 Aug;102(4):1151-61. doi: 10.1111/j.1471-4159.2007.04629.x.
3
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21.
5
Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors.
Neuropharmacology. 2007 Apr;52(5):1210-8. doi: 10.1016/j.neuropharm.2006.11.010. Epub 2007 Mar 26.
6
Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.
J Lipid Res. 2014 Dec;55(12):2665-75. doi: 10.1194/jlr.P054163. Epub 2014 Oct 7.
7
Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice.
J Clin Invest. 2011 Jun;121(6):2290-300. doi: 10.1172/JCI45403. Epub 2011 May 9.
8
Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
Cell Signal. 2007 Aug;19(8):1754-64. doi: 10.1016/j.cellsig.2007.03.011. Epub 2007 Apr 6.
9
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors.
Nat Chem Biol. 2009 Jun;5(6):428-34. doi: 10.1038/nchembio.173.
10
Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
Prostaglandins Other Lipid Mediat. 2004 Jan;73(1-2):29-45. doi: 10.1016/j.prostaglandins.2003.11.003.

引用本文的文献

1
Extramembranous Regions in G Protein-Coupled Receptors: Cinderella in Receptor Biology?
J Membr Biol. 2019 Oct;252(4-5):483-497. doi: 10.1007/s00232-019-00092-3. Epub 2019 Aug 30.
3
An update on sphingosine-1-phosphate receptor 1 modulators.
Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3585-3591. doi: 10.1016/j.bmcl.2018.10.042. Epub 2018 Oct 26.
5
Mitigation of radiation injury by selective stimulation of the LPA(2) receptor.
Biochim Biophys Acta. 2013 Jan;1831(1):117-25. doi: 10.1016/j.bbalip.2012.08.020.
6
Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions.
Biochim Biophys Acta. 2013 Jan;1831(1):2-12. doi: 10.1016/j.bbalip.2012.09.002. Epub 2012 Sep 12.
7
Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.
Biochim Biophys Acta. 2013 Jan;1831(1):157-66. doi: 10.1016/j.bbalip.2012.07.002. Epub 2012 Jul 16.

本文引用的文献

1
Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice.
J Clin Invest. 2011 Jun;121(6):2290-300. doi: 10.1172/JCI45403. Epub 2011 May 9.
2
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Neurology. 2011 Feb 22;76(8 Suppl 3):S3-8. doi: 10.1212/WNL.0b013e31820d5ec1.
3
Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
Neurology. 2011 Feb 22;76(8 Suppl 3):S28-37. doi: 10.1212/WNL.0b013e31820db40f.
4
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341.
5
Therapeutic potential of β-arrestin- and G protein-biased agonists.
Trends Mol Med. 2011 Mar;17(3):126-39. doi: 10.1016/j.molmed.2010.11.004. Epub 2010 Dec 21.
6
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):751-6. doi: 10.1073/pnas.1014154108. Epub 2010 Dec 21.
7
Extracellular and intracellular actions of sphingosine-1-phosphate.
Adv Exp Med Biol. 2010;688:141-55. doi: 10.1007/978-1-4419-6741-1_10.
9
Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions.
Cell Physiol Biochem. 2010;26(1):79-86. doi: 10.1159/000315108. Epub 2010 May 18.
10
Understanding the ligand-receptor-G protein ternary complex for GPCR drug discovery.
Methods Mol Biol. 2009;552:67-77. doi: 10.1007/978-1-60327-317-6_5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验